Suppr超能文献

右美托咪定在成人中的更新聚焦综述。

An updated focused review of dexmedetomidine in adults.

机构信息

Ohio State University Medical Center and Ohio State University, Columbus, OH, USA.

出版信息

Ann Pharmacother. 2009 Dec;43(12):2064-74. doi: 10.1345/aph.1M310.

Abstract

OBJECTIVE

To evaluate recent comparative studies regarding the safety and efficacy of dexmedetomidine in adults.

DATA SOURCES

Articles evaluating safety and efficacy of dexmedetomidine were identified from an English-language MEDLINE search (1996-July 2009), with a focus on data published since our previous review in 2007 to the present. MeSH terms included dexmedetomidine, medetomidine, alpha2-agonist, and sedation. References from selected articles were also reviewed for additional material.

STUDY SELECTION AND DATA EXTRACTION

Experimental and observational English-language studies that focused on the efficacy, safety, and pharmacoeconomics of dexmedetomidine in humans were selected.

DATA SYNTHESIS

Dexmedetomidine is an 2-agonist used for sedation during procedures and in critical illness. Compared with placebo, use of dexmedetomidine during procedures was associated with decreased use of rescue midazolam and a similar degree of sedation compared with various agents used during surgery or for procedures. Use of long-term (>24 h) dexmedetomidine sedation is comparable to sedation with benzodiazepines in critically ill patients. In a Phase 4 study, dexmedetomidine was safe in dosages up to 1.4 microg/kg/hour for greater than 24 hours and did not produce rebound tachycardia or hypertension when abruptly discontinued. One small randomized controlled trial demonstrated decreased incidence of delirium, the primary endpoint, with dexmedetomidine compared with midazolam or propofol for sedation after cardiac valve surgery. Many, but not all, studies suggest that dexmedetomidine has a promising role in prevention and treatment of delirium in critically ill patients when delirium was studied as a secondary endpoint.

CONCLUSIONS

Dexmedetomidine is an alternative for procedural sedation and can be used long-term (>24 h) in critically ill patients, in dosages up to 1.5 microg/kg/hour. More studies are needed to better define the role of dexmedetomidine in preventing and treating delirium.

摘要

目的

评估最近关于右美托咪定在成人中的安全性和有效性的比较研究。

资料来源

从英文 MEDLINE 搜索中确定了评估右美托咪定安全性和有效性的文章(1996 年-2009 年 7 月),重点是我们在 2007 年的上一次综述以来的数据。MeSH 术语包括右美托咪定、美托咪定、α2-激动剂和镇静。还对选定文章的参考文献进行了审查,以获取其他资料。

研究选择和资料提取

选择了重点关注右美托咪定在人体中的疗效、安全性和药物经济学的实验和观察性英文研究。

资料综合

右美托咪定是一种 2-激动剂,用于程序期间和危重病期间的镇静。与安慰剂相比,在程序期间使用右美托咪定与减少使用解救咪达唑仑和与手术期间或用于程序的各种药物相比类似程度的镇静相关。长期(>24 小时)使用右美托咪定镇静与苯二氮䓬类药物在危重病患者中相当。在一项 4 期研究中,右美托咪定在高达 1.4μg/kg/小时的剂量下使用超过 24 小时是安全的,并且当突然停药时不会产生反弹性心动过速或高血压。一项小型随机对照试验表明,与咪达唑仑或丙泊酚相比,右美托咪定用于心脏瓣膜手术后镇静时,主要终点(即谵妄发生率)降低。许多(但不是全部)研究表明,当将谵妄作为次要终点进行研究时,右美托咪定在预防和治疗危重病患者的谵妄方面具有有前途的作用。

结论

右美托咪定是一种替代方案,可用于程序镇静,并且可以在危重病患者中长期(>24 小时)使用,剂量高达 1.5μg/kg/小时。需要更多的研究来更好地确定右美托咪定在预防和治疗谵妄中的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验